Article
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
Oncotarget - 4 Jul 2017
Urso Loredana, Cavallari Ilaria, Silic-Benussi Micol, Biasini Lorena, Zago Giulia, Calabrese Fiorella, Conte Pier Franco, Ciminale Vincenzo, Pasello Giulia
Abstract excerpt
Malignant Pleural Mesothelioma (MPM) is a chemoresistant tumor characterized by low rate of p53 mutation and upregulation of Murine Double Minute 2 (MDM2), suggesting that it may be effectively targeted using MDM2 inhibitors. In the present study, we investigated the anticancer activity of the MDM2 inhibitors Nutlin 3a (in vitro) and RG7112 (in vivo), as single agents or in combination with rhTRAIL.In vitro...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.